Teva Pharmaceutical Industries Limited (TEVA) Stake Raised by Financial Counselors Inc.

Financial Counselors Inc. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 140,599 shares of the company’s stock after buying an additional 7,571 shares during the period. Financial Counselors Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $4,671,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Alliancebernstein L.P. boosted its stake in Teva Pharmaceutical Industries Limited by 32.3% during the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after buying an additional 2,782,257 shares during the last quarter. Franklin Resources Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares during the last quarter. CIBC World Markets Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 13.0% during the second quarter. CIBC World Markets Inc. now owns 246,941 shares of the company’s stock valued at $8,203,000 after buying an additional 28,423 shares during the last quarter. AGF Investments Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 21.6% during the second quarter. AGF Investments Inc. now owns 1,884,366 shares of the company’s stock valued at $62,623,000 after buying an additional 335,122 shares during the last quarter. Finally, Schroder Investment Management Group boosted its stake in Teva Pharmaceutical Industries Limited by 10.5% during the second quarter. Schroder Investment Management Group now owns 5,046,400 shares of the company’s stock valued at $165,673,000 after buying an additional 478,971 shares during the last quarter. 56.87% of the stock is owned by institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 1.42% during mid-day trading on Friday, reaching $18.10. The company’s stock had a trading volume of 20,967,151 shares. The stock’s market capitalization is $18.39 billion. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $51.61. The company’s 50-day moving average is $19.00 and its 200-day moving average is $28.55.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.25 earnings per share. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://ledgergazette.com/2017/09/17/teva-pharmaceutical-industries-limited-teva-shares-bought-by-financial-counselors-inc.html.

A number of brokerages recently commented on TEVA. Maxim Group reissued a “hold” rating and set a $15.50 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday. UBS AG restated a “neutral” rating and set a $19.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday. Gabelli restated a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, September 11th. Five analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $31.42.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply